Phase 2 Relapsed or Refractory Peripheral T-cell Lymphoma Clinical Trials
3 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–3 of 3 trials
Recruiting
Phase 2
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Relapsed or Refractory Peripheral T-cell Lymphoma
Great Novel Therapeutics Biotech & Medicals Corporation33 enrolled5 locationsNCT05833724
Recruiting
Phase 1Phase 2
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Genfleet Therapeutics (Shanghai) Inc.95 enrolled1 locationNCT05934513
Terminated
Phase 2
Trial of KPT-330 in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) and Cutaneous T cell Lymphoma (CTCL)
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Relapsed or Refractory Cutaneous T cell Lymphoma (CTCL)
Karyopharm Therapeutics Inc.30 enrolled4 locationsACTRN12614001328662